

#9

REMARKS

Applicants enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing.

The specification has been amended to provide a SEQ ID NO for the sequence disclosed therein. This submission contains no new matter.

In accordance with 37 CFR § 1.821(f) I hereby state that the content of the paper and computer readable copies of the Sequence Listing are the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: February 21, 2002

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

"MARKED-UP" VERSION OF AMENDMENTS TO SPECIFICATION

Please replace the paragraph at page 7, line 25 to page 8, line 2 with the following:

--In a further embodiment of the invention the GLP-1 analogue has the formula

(SEQ ID NO: 1) II:

7 8 9 10 11 12 13 14 15 16 17

His-Xaa-Xaa-Gly-Xaa-Phe-Thr-Xaa-Asp-Xaa-Xaa-

18 19 20 21 22 23 24 25 26 27 28

Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Phe-

29 30 31 32 33 34 35 36 37 38

Ile-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa

39 40 41 42 43 44 45

Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa

(II)--